Targeted LNP Solution for in vivo CAR-T Therapy

Targeted LNP Solution for in vivo CAR-T Therapy

Size, empty/full ratio, mRNA copy number, encapsulation efficiency and ligand density.

Fluorescence Quantitation Beads

Fluorescence Quantitation Beads

Verify sensitivity, resolution and quantitation.

LV Characterization for in vitro & in vivo CAR-T

LV Characterization for in vitro & in vivo CAR-T

p24, VSV-G and nucleic acid characterized simultaneously.

Single-Molecule NanoAnalyzer Auto 20

Single-Molecule NanoAnalyzer Auto 20

Unlock Reliable and Reproducible Analysis of Quantitative Multicomponent Detection.

Application and Solutions

View more

Single-Particle Analytics for Targeted LNP (tLNP) Engineering

In Vivo CAR-T LNP Solution

Targeted LNPs bearing T-cell–directing ligands (antibodies, targeting peptides, aptamers, or small molecules) deliver CAR-encoding mRNA or gene-editing cargo straight to the patient's own T cells in vivo, eliminating ex vivo cell manufacturing altogether.

View solution
LV Characterization Solution for CAR-T

LV Characterization Solution for CAR-T

LVs are the workhorse of CAR-T engineering. Derived from HIV-1 (80–120 nm), they were used in over 150 active CAR-T clinical trials as of 2026 across the United States, China, the European Union, and Canada, and served as the delivery vehicle for 8 of the 9 globally approved CAR-T products. Regulators including the FDA and NMPA's Center for Drug Evaluation require rigorous control of titer, identity, purity, potency, and safety — demanding comprehensive single-particle characterization across the full product lifecycle. Label-free scattering of a typical LV sample returned 3.17 × 10⁹ particles/mL at a mean diameter of 86.0 nm in 1–2 minutes, with gradient dilution showing excellent linearity (R² = 0.997).

View solution
Stem Cell-Derived EV Characterization Solution

Stem Cell-Derived EV Characterization Solution

Stem cell-derived extracellular vesicles (SC-EVs) mediate tissue repair, immunomodulation and disease treatment, and are emerging as a leading “acellular therapy” for regenerative medicine — with over 100 clinical trials registered to date (ClinicalTrials.gov, Feb 2026). Their translation, however, is bottlenecked by one question: how to precisely characterize particle size, concentration, purity and surface markers.

View solution

Product Center

NanoAnalyzer

Single-Molecule NanoAnalyzer

  • High-throughput
  • Automatic clean-up
  • Up to 3 markers

Fluorescent quantitation
Nucleic acid copy number per LNP
Copy number of specific proteins
Encapsulation efficiency

Reagents Consumables

  • Quality Control
  • Size Standard
  • Fluorescent quantitation
  • Fluorescent Antibody

Meet the NanoAnalyzer family

NanoAnalyzer
Single-Molecule NanoAnalyzer
Reagents Consumables

Webinars & Latest News

NanoFCM Analysis of Targeted Particles for Extrahepatic Delivery

NanoFCM Analysis of Targeted Particles for Extrahepatic Delivery

The rapid development of nanoparticles engineered for extrahepatic delivery has created a growing need for analytical methods capable of resolving increasingly complex particle formulations. Conventional bulk measurements provide valuable information but may o…

Date :
September 29, 2026
Time :
11:00 AM PT, 2:00 PM EDT, 8:00 PM CET

REGISTER NOW

Previous Reviews

CONTACT

  • Request a Demo
  • Request a Quote
  • Request Sample Analysis
  • Request Technical Information
  • Request a Call Back
  • Request Technical Service

0+

Countries

0+

Top Users

0%

TOP 20 Biopharma

0+

Publications